KRTX - Bristol Myers Squibb Scoops Up Schizophrenia Player Karuna Therapeutics In Massive $14B Deal | Benzinga
On Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Karuna is focused on developing treatments for psychiatric and neurological conditions. Karuna's lead asset, KarXT (xanomeline-trospium), is an antipsychotic.
A New Drug Application (NDA) for KarXT for schizophrenia in adults was accepted for review by the FDA, with a Prescription Drug User Fee Act date of September 26, 2024.
KarXT is also in registrational trials both for adjunctive therapy ...